Results 1 to 10 of about 14,945 (175)

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC [PDF]

JTO Clinical and Research Reports
Introduction: Canakinumab is a human monoclonal anti–interleukin-1β antibody with the potential to enhance the activity of programmed death-ligand 1 inhibitors by inhibiting protumor inflammation.
Jay M. Lee, MD, Jean-Louis Pujol, MD, PhD, Jun Zhang, MD, PhD, Oleg Leonov, MD, PhD, Masahiro Tsuboi, MD, PhD, Edward S. Kim, MD, MBA, Calvin Ng, MD, Nicolas Moreno-Mata, MD, PhD, Amy Cummings, MD, PhD, Ilhan Hacibekiroglu, MD, Abidin Sehitogullari, MD, Nirmal Veeramachaneni, MD, Cathy Spillane, PhD, Jiawei Duan, PhD, Claudia Bossen, PhD, Alexander Savchenko, MD, PhD, Chiara Lobetti-Bodoni, MD, PhD, Tony Mok, MD, Pilar Garrido, MD   +18 more
doaj   +2 more sources

Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry [PDF]

Pediatric Rheumatology Online Journal
Background Systemic juvenile idiopathic arthritis (SJIA) is a severe form of juvenile idiopathic arthritis characterized by fever, rash, chronic arthritis, and systemic inflammation.
Colleen Correll, Alis Burciu, Amita Bansal, Anne Dennos, Deepak Narayanswamy, Elodie Aubrun, Laura E. Schanberg, Li Yuhan, Rahel Schneider, Stephen Balevic, Yukiko Kimura, Timothy Beukelman, for the CARRA Registry investigators   +12 more
doaj   +2 more sources

Long-term Effectiveness and Safety of Canakinumab in Patients with TRAPS: Analysis of the RELIANCE Non-Interventional Study [PDF]

Rheumatology and Therapy
Introduction This is an interim analysis of the long-term effectiveness and safety of canakinumab in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) cohort of the RELIANCE non-interventional study.
Norbert Blank, Catharina Schuetz, Markus Hufnagel, Gerd Horneff, Michael Borte, Tilmann Kallinich, Prasad T. Oommen, Ales Janda, Joerg Henes, Julia Weber-Arden, Michael Stock, Jasmin B. Kuemmerle-Deschner   +11 more
doaj   +2 more sources

Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study [PDF]

BMC Rheumatology
Background Canakinumab, an IL-1β inhibitor, has demonstrated long-term efficacy and safety in patients with sJIA, FMF, TRAPS, and MKD/HIDS who experience inadequate disease control with conventional treatments. This non-interventional study aimed to gain
Michel Moutschen, Cécile Boulanger, Joke Dehoorne, Rik Joos, Florence Roufosse, Vito Sabato, Jeroen van der Hilst, Eleonore Maury, Hilde Rabijns, Marijn Witterzeel, Carine Wouters   +10 more
doaj   +2 more sources

Neonatal-onset multisystem inflammatory disease caused by a de novo NLRP3 gene mutation: a case report and literature review [PDF]

Frontiers in Pediatrics
BackgroundNeonatal-onset multisystem inflammatory disease (NOMID) is a rare autoinflammatory disease caused by NLRP3 mutations, leading to excessive interleukin-1β activation and potential irreversible organ damage.Case descriptionWe report a female ...
Lingxia Zhao, Lingkong Zeng, Wenhao Yuan
doaj   +2 more sources

Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system [PDF]

Frontiers in Pharmacology
BackgroundAnakinra and canakinumab are two FDA-approved IL-1 blockers indicated for the treatment of multiple autoinflammatory diseases, yet their safety has not been comprehensively analyzed.
Hao Liu, Wei Yan, Jinsong Li, Dezhi Yan, Di Luo   +4 more
doaj   +2 more sources

The effect of IL-1β inhibitor canakinumab (Ilaris®) on IL-6 production in human skeletal muscle cells. [PDF]

PLoS ONE
Muscle inflammation is one of the hallmarks of Duchenne muscular dystrophy (DMD). Dystrophin-deficient skeletal muscle cells produce higher levels of pro-inflammatory cytokines such as interleukin 1β (IL-1β) in response to toll-like receptor stimulation ...
Anna Cordeiro-Santanach, Fiorella Morales, Maria Del Carmen Parquet, Kitipong Uaesoontrachoon, Joyce Rowsell, Jordan Warford, Wilson Wu, Pia Elustondo, Eric P Hoffman, Kanneboyina Nagaraju   +9 more
doaj   +2 more sources

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) [PDF]

Pharmaceuticals
Background: Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential.
Weidong Zhang, Yunzhou Chen, Zeyu Yao, Mengling Ouyang, Minghui Sun, Shupeng Zou   +5 more
doaj   +2 more sources

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases

Frontiers in Pediatrics, 2021
Anti-interleukin 1 agents are used successfully in colchicine-resistant or intolerant Familial Mediterranean Fever (FMF) patients. Sixty-five patients with FMF who received canakinumab treatment for at least 6 months due to colchicine resistance or ...
Burcu Bozkaya Yücel, Ozlem Aydog, Ozlem Aydog, Hulya Nalcacioglu, Ayşegül Yılmaz   +4 more
doaj   +1 more source

Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States

Pediatric Rheumatology Online Journal, 2021
Background Although canakinumab has demonstrated efficacy in multiple trials in patients with periodic fever syndromes (PFS), the evidence on initiation of canakinumab among PFS patients in real world setting is not well understood.
Peter Hur, Kathleen G. Lomax, Raluca Ionescu-Ittu, Ameur M. Manceur, Jipan Xie, Jordan Cammarota, Raju Gautam, Navneet Sanghera, Nina Kim, Alexei A. Grom   +9 more
doaj   +1 more source